Clarity Pharmaceuticals (ASX:CU6): Executive Chair Dr Alan Taylor on Phase 3, Co-PSMA & the Future of Prostate Cancer ImagingUntitled episode
Further Reading & Listening 🎧 GU Cast | Urology Podcast – "Is Copper the new Gold??! Co-PSMA trial in European Urology" https://www.podchaser.com/podcasts/gu-cast-urology-podcast-2221144/episodes/is-copper-the-new-gold-co-psma-292293994 📄 European Urology – Co-PSMA Trial Publication https://doi.org/10.1016/j.eururo.2026.03.001 These resources were referenced during the webinar and provide additional clinical context around the Co-PSMA trial and the development of Cu-64 SAR-bisPSMA. Can Clarity Pharmaceuticals (ASX:CU6) become a global leader in radiopharmaceuticals for prostate cancer? In…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.